Strategies to reduce cardiac toxicity
E. Coletti Moia
Vol.7 (2022), issue 1, pag. 119 - 124
| Received | 2/08/2021 |
| Accepted | 2/01/2022 |
| Published | 24/03/2022 |
| Review by | Double-blind |
| DOI | https://doi.org/10.48253/AGO24 |
ABSTRACT
Some therapies which are required to cure breast cancer or to con- trol it chronically are cardiotoxic. Left ventricular dysfunction (LVD) and heart failure (HF) are two of the most serious complications of cancer treatment, if they occur during treatment, they may lead to treatment interruption and interfere with optimal cancer care. Prior to treatment is important to assess the risk of oncology patients; during cardiotoxic cancer and throughout follow-up to employ sur- veillance strategies (the two most widely studied strategies for sur- veillance and early detection are measurement of cardiac biomark- ers and cardiac imaging). Early detection and implementation of cardiovascolar (CV) risk factor management and cardioprotective treatment strategies, where appropriate, are necessary to support the best cancer treatment.